3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
23
Kidney Neoplasms
10
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Carcinoma
6
Melanoma
4
Lung Neoplasms
4
Colorectal Neoplasms
4
Neoplasm Metastasis
3
Carcinoma, Hepatocellular
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Kidney Diseases
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Adenoid Cystic
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Interventions
Sunitinib
3
avelumab
2
Nutrition Assessment
2
Axitinib
2
spartalizumab
1
pembrolizumab
1
etelcalcetide hydrochloride
1
aldesleukin
1
Sorafenib
1
Resistance Training
1
Plasma Exchange
1
Interleukin-2
1
Adalimumab
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Kidney Diseases
×
Axitinib
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts